INTRODUCTION {#s1}
============

Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumours, with a median survival of 6 months and steadily increasing incidence rates in the industrialized world, and thus represents one of the major challenges in cancer medicine \[[@R1]\]. About 103,000 new cases are diagnosed each year in Europe (see data of the European Cancer Observatory at <http://eco.iarc.fr/eucan/Default.aspx>), and 44,000 in the USA \[[@R1]\]. Currently, by the time a definitive diagnosis is reached, most PDAC patients have locally advanced or metastasized disease, and are therefore not candidates for surgical resection \[[@R2]\]. Surgical resection of early-stage tumors is thus the only available potentially curative treatment option \[[@R2]\] \[[@R3]\], and there is an urgent need to develop early detection methods to increase the fraction of patients diagnosed in a curative stage to improve the overall outcomes of PDAC patients. Furthermore, although PDAC accounts for the majority of all malignant tumors in the pancreas \[[@R4]\], other neoplasms of the pancreatico-biliary system that display a wide range of biological behaviors and clinical outcomes are increasingly being recognized. Benign processes such as inflammatory masses developing in the course of chronic pancreatitis or autoimmune pancreatitis \[[@R5]\] \[[@R6]\] may cause the same signs and symptoms as malignant neoplasms. Both the timely detection and the accurate differential diagnosis of suspect masses in the pancreas are thus critical in order to avoid unnecessary delays in therapy decisions as well as potentially harmful over- or undertreatment of patients.

Presently, when the diagnosis of a suspect mass in the pancreas remains unclear, endoscopic ultrasonographyfine needle aspiration (EUS-FNA) is considered as the standard to confirm or exclude malignancy. In centers providing special requirements such as highly trained endoscopists proficient in EUS-guided biopsy approaches, equipment and on-site cytology will reach specificity of up to 96% and sensitivity of up to 87% as reported by recent systematic meta-analyses \[[@R7]\], \[[@R8]\]. However, specificity for the diagnosis of malignancy reported in the literature ranges between 80 and 100%, while sensitivity is much more variable with an overall low and variable negative predictive value (33-85%) \[[@R9]\]. Many factors can impact the diagnostic yield of EUS-FNA including the experience of both the endosonographer and cytologist, availability of on-site cytology, and the inherent limitations of the procedure to identify cytomorphologic features characteristic of well-differentiated cancer, in particular in the setting of chronic pancreatitis (CP). Sensitivity can be also compromised by technical factors such as sampling errors, insufficient cellularity, and the presence of fibrosis or blood \[[@R10]\].

New molecular approaches offer the promise of accuracy, straight-forward distribution, and affordability that will be needed to deliver practical screening tools. We have previously demonstrated that multiple types of pancreatico-biliary tumors comprising ampullary cancers, solid pseudopapillary tumors, adenocarcinomas of the distal bile duct, and inflammatory masses developing in chronic pancreatitis can be accurately differentiated via their mRNA expression profile obtained from biopsy specimens using cDNA arrays \[[@R11]\]. Furthermore, next generation transcriptome sequencing approaches have revealed the existence of PDAC subtypes that are of prognostic, and most likely therapeutic, relevance (\[[@R12]\], \[[@R13]\], \[[@R14]\], \[[@R15]\]). In addition to mRNA profiles, microRNAs (miRNAs) have evolved as promising biomarker molecules for cancer detection. miRNAs are highly regulated in cancer, are very stable in tissue, plasma, stool, and other fluids and can be quantified in very small sample sizes. They have extensively been studied for their role as diagnostic, prognostic or predictive biomarkers in pancreatic cancer which has been reviewed elsewhere \[[@R16]\], \[[@R17]\], \[[@R18]\], \[[@R19]\], \[[@R20]\], \[[@R21]\], \[[@R22]\]). However, RNA or miRNA molecular diagnostics have so far neither entered routine clinical applications nor have been used in combination to enhance their diagnostic power. Here, we present a quantitative real-time PCR-based multi-omics molecular platform that combines the classification potential of mRNA and miRNA expression patterns for the differentiation of malignant and benign pancreaticobiliary tumors in minimal amounts of biopsy material.

RESULTS {#s2}
=======

Generation of combined microRNA and mRNA biomarker microfluidic arrays {#s2_1}
----------------------------------------------------------------------

As mentioned above, we have previously reported that accurate molecular diagnostic classification of multiple pancreatico-biliary tumors by analysis of mRNA expression profiles from clinical samples is possible using custom cDNA arrays \[[@R11]\]. In order to transfer this diagnostic principle to a standardized and uniformly available technological platform, we established simultaneous analysis of mRNA and miRNA expression on a single TaqMan® Array microfluidic card (\[[@R23]\]; see Materials and Methods). mRNA markers to be included in the array were selected from our previous study \[[@R11]\]; 9 miRNA markers (miR-1246, miR-135b, miR-196a, miR-210, miR217, miR-155, miR-203, miR-148a, miR375) were selected from our unpublished data as well as reports from the literature (summarized in \[[@R22]\], \[[@R19]\], \[[@R17]\], \[[@R18]\], \[[@R16]\], \[[@R24]\], \[[@R25]\], \[[@R26]\], \[[@R20]\]). The final composition of the mixed TaqMan Array comprised 79 mRNA markers, 5 mRNA reference genes, 9 miRNA markers, and 2 small RNA reference genes (Table [1](#T1){ref-type="table"}).

###### Composition of the mixed TaqMan^®^ Array

  Gene Name      Role
  -------------- ------------------
  ACTG1          Marker
  AMFR           Marker
  ASNS           Marker
  ATP7B          Marker
  BAMBI          Marker
  BCL2L1         Marker
  CASP6          Marker
  CDC2           Marker
  CDH1           Marker
  CDH3           Marker
  18S-rRNA       Internal Control
  CEACAM7        Marker
  CLDN1          Marker
  CLDN3          Marker
  CLDN4          Marker
  CLDN9          Marker
  CLK1           Marker
  CTGF           Marker
  CTSC           Marker
  CTSE           Marker
  CYB561         Marker
  DUSP3          Marker
  DUSP8          Marker
  E2F1           Marker
  EGFR           Marker
  ELA3A,ELA3B    Marker
  EPCAM          Marker
  F3             Marker
  FGF2           Marker
  GPR68          Marker
  GRB10          Marker
  GSTA2          Marker
  HMGN2          Marker
  HSF2           Marker
  HSP90B1        Marker
  IL6            Marker
  ILKAP          Marker
  INPPL1         Marker
  KLRB1          Marker
  KRT17          Marker
  KRT7           Marker
  LDHA           Marker
  MAD2L1         Marker
  MAP2K4         Marker
  MMP2           Marker
  MUC3A,MUC3B    Marker
  MYC            Marker
  NFATC1         Marker
  PHLDA1         Marker
  PPP1R1A        Marker
  PPP2R5C        Marker
  PTGFR          Marker
  PVRL1          Marker
  RAF1           Marker
  RHOBTB3        Marker
  SDC1           Marker
  SERPIND1       Marker
  SH3BP1         Marker
  SLC19A1        Marker
  SMARCA1        Marker
  SPARC          Marker
  STC1           Marker
  TF             Marker
  TGIF1          Marker
  TJP3           Marker
  TNC            Marker
  TNFAIP3        Marker
  TP53           Marker
  USP12          Marker
  VIM            Marker
  ZNF91          Marker
  TMPRSS4        Marker
  MST1R          Marker
  NT5E           Marker
  RALB           Marker
  TRIO           Marker
  EZH2           Marker
  MELK           Marker
  PAK4           Marker
  RRAS           Marker
  RPLP0          Reference
  PPIA           Reference
  RPL37A         Reference
  RPL30          Reference
  RPS17          Reference
  hsa-mir-1246   Marker
  hsa-mir-135b   Marker
  hsa-mir-196a   Marker
  hsa-mir-210    Marker
  hsa-miR-217    Marker
  hsa-miR-155    Marker
  hsa-miR-203    Marker
  hsa-miR-148a   Marker
  hsa-miR-375    Marker
  RNU44          Reference
  RNU48          Reference

Evaluation of the mRNA/miRNA microfluidic array in surgical FNAB for the differentiation of ductal adenocarcinoma and chronic pancreatitis {#s2_2}
------------------------------------------------------------------------------------------------------------------------------------------

The first goal of the study was to allow an accurate molecular differentiation between PDAC and CP using fine needle aspiration biopsy samples obtained directly from tumor masses during surgery. These "surgical FNAB" (sFNAB) samples ensure both accurate targeting of the tumor mass and subsequent histological confirmation of the diagnosis in the same bioptic tissue specimen. At the same time, sFNAB closely resemble "real" FNAB samples obtained during routine diagnostic procedures in both cellular composition and overall yield of diagnostic material. A total of 113 samples from patients undergoing surgery for pancreatic masses were prospectively collected at the participating centers, including 41 from PDAC and 33 from CP patients, and subsequently subjected to gene expression analysis using the mixed TaqMan® Array (Figure [1](#F1){ref-type="fig"}).

![Study design](oncotarget-08-108223-g001){#F1}

In the first step of the analyses, we concentrated on the differentiation between PDAC and CP, since this is the clinically most relevant differential diagnosis. Since the selected miRNA markers had previously been reported to have high diagnostic potential on their own, we first sought to determine whether miRNA marker analysis alone would be sufficient to accurately discriminate between PDAC and CP. To this end, all possible combinations of the 9 miRNA markers (single markers, double combinations, triple combinations, and so on up to combination of all nine markers) were used to construct molecular classifiers by generating multivariate decision rules using support vector machines (SVM). Decision boundaries (= high dimensional hyperplanes) separating the two diagnostic classes were defined such that the margins between the samples of the diagnostic classes were maximized. In order to avoid overfitting of the resulting classifiers to the specific data set and to obtain an estimate of the general performance of each classifier, we performed 10×10-fold cross validation analyses. The data set was thus repeatedly randomly divided into independent training and test sets, each time training the classifier with 90% of the data and testing the diagnostic performance on the remaining 10% of samples, respectively, thereby creating a total of 100 different combinations of independent training and test sets for each candidate classifier. In the 100 independent test runs, the predicted diagnoses for all samples of the test sets were recorded and compared to their true diagnoses (using histopathological diagnosis as gold standard), resulting in a total of 740 data points for each 10×10-fold cross validation run (schematically outlined in Figure [2](#F2){ref-type="fig"}). Using this very stringent evaluation procedure, the best-performing classifier achieved an overall accuracy of differential diagnosis of 75% (Figure [3](#F3){ref-type="fig"}).

![Schematic representation of 10×10 cross validation procedure\
The original dataset is split into ten subsets of approximately equal size. Nine of these subsets are used for training the classification model (SVM). The tenth subset is used as an independent subset for evaluating the performance of the trained classifier. This procedure is repeated for each subset and an overall accuracy is calculated as the mean accuracy over ten permutations of the original dataset.](oncotarget-08-108223-g002){#F2}

![Exhaustive evaluation of all miRNA marker combinations\
All possible combinations of miRNA markers, from single miRNAs to the combination of all 9 markers (2^9^-1 = 511 possible combinations), were tested for their diagnostic performances on the set of PDAC and CP samples. Each combination was evaluated by a linear SVM and sensitivity, specificity and diagnostic accuracy determined by 10×10-fold cross validation. Results are plotted in decreasing order according to accuracy. Note that none of the resulting classifiers exceeded a diagnostic accuracy of 75%, with the best-performing combination achieving a sensitivity of 58.5% and a specificity of 88.3%. "CP" = chronic pancreatitis; "PDAC" = pancreatic ductal adenocarcinoma; "Acc" = accuracy; "Sens" = sensitivity; "Spec" = specificity.](oncotarget-08-108223-g003){#F3}

We next analysed the complete set of combined miRNA and mRNA expression data for its ability to differentiate between PDAC and CP samples. Unsupervised hierarchical clustering of the mRNA and miRNA gene expression data already showed a strong tendency for the samples to separate into two large clusters of PDAC and CP cases, with 13 out of 75 samples being placed on the "wrong" side of the cluster tree using this very simple analysis (Figure [4](#F4){ref-type="fig"}). In order to optimize classification, we again constructed SVM models as described above. However, exhaustive search of all possible combinations of the total set of 88 markers was not feasible due to the high number (=3,09^\*^10^26^) of possible combinations. The individual markers were therefore ranked according to the sensitivity and specificity of univariate single threshold classifiers (TNoM~cw~-score), and a series of multivariate SVM classifiers was constructed by including increasing numbers of markers (1 to 88 markers, starting with the highest TNoM~cw~-score). The construction and training of classifiers is schematically outlined in Figure [5](#F5){ref-type="fig"}. To obtain a conservative estimate of the general performance of the classification system, we again performed 10×10-fold cross validation analyses as described above. This very rigorous evaluation procedure, which created conditions that were even more demanding than would be expected in a routine clinical scenario, revealed very good diagnostic accuracies (≥ 90.0%) for a number of classifiers comprising 74 to 85 individual markers. The highest score was recorded for a combination of 77 individual markers, with a sensitivity for the detection of PDAC of 91.7%, a specificity of 94.5%, and an overall diagnostic accuracy of 93.0% in the 10×10-fold cross validation (Figure [6](#F6){ref-type="fig"}). This classifier was thus chosen as the final diagnostic algorithm to be used in future clinical application.

![Unsupervised clustering of expression profiles from PDAC and CP biopsies\
Individual samples are shown in columns; genes are shown in rows. Both the samples and the genes were hierarchically clustered (complete linkage clustering) using uncentered Pearson correlation as the similarity measure. Red cells indicate high expression, black intermediate expression, and green low expression of a gene in the respective group. Clusters of CP (blue bars) and PDAC samples (yellow bars) are readily apparent. "CP" = chronic pancreatitis; "PDAC" = pancreatic ductal adenocarcinoma.](oncotarget-08-108223-g004){#F4}

![Training of mixed miRNA / mRNA classifiers\
Combined profiles of miRNA and mRNA markers (Panel i) were analyzed in a sequence of marker selection and classification experiment. First, a subset of candidate markers was selected via the univariate TNoM~cw~ score (Panel ii). The reduced marker profiles were then used to train a multivariate SVM (Panel iii). The final decision can be projected to univariate space (Panel iv).](oncotarget-08-108223-g005){#F5}

![Evaluation of the combined miRNA/mRNA marker profiles\
Accuracy, sensitivity and specificity gained in the 10×10 cross validation experiments with the combined miRNA/mRNA marker profiles. Classification models vary in the number of markers that were selected during their training phases. Results are given in increasing order from 1 to 88 selected biomarkers. Accuracies ≥ 90% are marked in yellow. "CP" = chronic pancreatitis; "PDAC" = pancreatic ductal adenocarcinoma.](oncotarget-08-108223-g006){#F6}

Evaluation of the established mRNA/miRNA classifier for identification of malignant tumors other than PDAC {#s2_3}
----------------------------------------------------------------------------------------------------------

During the prospective collection of samples for this study, all patients presenting with suspect masses in the pancreas were enrolled (Figure [1](#F1){ref-type="fig"}). A total of 39 sFNAB samples from patients for whom histopathological evaluation revealed a final diagnosis other than PDAC or chronic pancreatitis were thus also collected. The finalized diagnostic algorithm was subsequently also applied to analyze these samples. The results demonstrated that 3 of 3 ampullary carcinomas, 3 of 3 acinar cell carcinomas, and 5 of 5 biliary tract carcinomas were assigned to the "PDAC" class, thus being classified as malignant with 100% accuracy (Figure [7](#F7){ref-type="fig"}). In contrast, cystadenomas and IPMNs (regardless of benign or malignant status) were evenly distributed between both groups, while 3 of 3 solid pseudopapillary tumor cases were assigned to the benign ("CP") class, indicating that the marker combination and diagnostic algorithm is less suited for the diagnostic analysis of cystic lesions.

![Performance of the final classifier in identifying malignancy on biopsy samples from pancreatobiliary tumors other than PDAC\
Retraining of the optimal model (77 markers) on all available samples. Prediction of PDAC and CP samples and categorization of all remaining tissue-types is given. "CP" = chronic pancreatitis; "PDAC" = pancreatic ductal adenocarcinoma; "CA" = carcinoma; "IPMN" = intraductal papillary mucinous neoplasm; "SPT" = solid pseudopapillary neoplasia.](oncotarget-08-108223-g007){#F7}

DISCUSSION {#s3}
==========

Currently, two major aspects are thought to contribute to the failure of diagnosis and treatment of PDAC: 1) The Genome Project has revealed that PDAC is the tumor with the highest degree of intertumoral genetic heterogeneity \[[@R14], [@R27]\], suggesting that no single molecular biomarker and no single molecular targeted therapy will work for diagnosis and treatment of all PDAC patients. 2) PDAC is an extremely stroma-rich tumor and up to 90% is made up of a highly complex assembly of activated fibroblasts, immune cells, blood vessels, neural cells and a variety of matricellular proteins \[[@R28]\] which contributes to therapy resistance and hinders cytological or histological diagnoses of PDAC in EUS-FNA. Accurate molecular differentiation of pancreatic cancers will thus likely require a high degree of multiplexing of markers to account for these variabilities.

At present, EUS FNA/FNAB of a pancreatic mass that is deemed resectable is not routinely performed \[[@R29]\], \[[@R30]\], \[[@R8]\], since a negative result cannot exclude the presence of PDAC due to the variable and low negative predictive values and will thus still lead to resection of the mass. Furthermore, there is always concern to induce tumor spreading along the biopsy channel. Tumor seeding with EUS-FNA has been reported, but the risk appears to be as small as 0,003-0,009% \[[@R31]\], and preoperative EUS-FNA has not been reported to be associated with adverse perioperative or long-term outcomes in patients undergoing resections for solid neoplasms of the pancreas \[[@R32]\]. Furthermore, neoadjuvant treatments for resectable or borderline resectable tumors or induction chemotherapies for downstaging of locally advanced non-resectable cases (\[[@R2]\], \[[@R33]\], \[[@R34]\], \[[@R35]\], \[[@R36]\], \[[@R37]\]) offer the promise of improving the outcome of PDAC patients. In such situations confirmation of the PDAC-diagnosis is mandatory before initiating neoadjuvant treatment. Thus, while currently not recommended, EUS-FNA of resectable pancreatic tumors in operable patients is likely to be invaluable for future molecular diagnosis and patient stratification if diagnostic accuracy can be substantially improved.

Multiple studies have previously been performed to evaluate the diagnostic performance of mRNA and miRNA biomarkers in PDAC. However, most of these studies were either not done in FNA material (using FFPE material instead), or did not have histopathology of all cases available to validate the biomarker results (e.g. \[[@R22]\], \[[@R20]\], \[[@R19]\]). We report here for the first time the simultaneous qRT-PCR-based analysis of miRNA and mRNA markers on a single microfluidic platform, interrogating FNAB samples for which detailed histopathological evaluation as gold standard is available.

Suitability of the mRNA/miRNA multi-omics platform for the diagnosis of malignancy in various pancreatic-biliary tumors {#s3_1}
-----------------------------------------------------------------------------------------------------------------------

In addition to the high sensitivity of marker detection inherent to the qRT-PCR-based technology, TaqMan Array cards are highly standardized and require limited hands-on time, making them a suitable platform for point-of-care diagnostic tests to be used in clinical routine. Our results confirm that this technology and the combined set of selected miRNA and mRNA markers is suitable to accurately distinguish between malignant and benign processes affecting the pancreas based on molecular analysis of FNAB samples. In the initial analysis of the total set of 74 PDAC and CP biopsy samples using a defined set of classifiers, we achieved a diagnostic accuracy of 100%, confirming the suitability of the multi-omics platform. The generalization ability of the support vector machine-based diagnostic algorithm, i.e., the question how accurately the algorithm would classify novel samples not previously used for training of the classifier, was addressed by performing a very rigorous 10×10-fold cross-validation procedure. This method provides a conservative estimate of the diagnostic performance that can be expected in a routine clinical setting, since 100 different combinations of independent training and test sets are interrogated, and every single misclassification event contributes to lowering of the accuracy score. In these analyses, our diagnostic system proved to be very robust, particularly in the two-class diagnostic scenario (malignant vs. benign pancreatic tumor), achieving a sensitivity of 91.7%, a specificity of 94.5%, and a diagnostic accuracy of 93.0%.

Moreover, our analyses revealed that combined classifiers comprising mRNA and miRNA markers were highly superior to classifiers based exclusively on previously reported miRNA markers. Our results for the miRNA-only classifier (75% accuracy of differentiation between PDAC and CP in 10×10fold cross validation) are in line with previous studies. Frampton and coworkers demonstrated a sensitivity of 81.5% and a specificity of 85.7% (AUC 0.930) for a 2-miRNA classifier (miR21 + miR-155) in distinguishing benign from malignant pancreatic lesions in EUS-FNAs \[[@R22]\]. Brand et al. reported that a 5-miRNA classifier (miR24, miR130B, miR135B, miR148A, and miR196) combined with standard cytology was able to improve the detection of PDAC to 90.8% \[[@R21]\]. Neither study, however, employed 10×10fold cross validation to assess the generalization ability of their classifiers.

In addition to being superior to "single omics" diagnostics in differentiating malignant from benign pancreatic masses, combining mRNA and miRNA biomarkers in a single mullti-omics molecular diagnostic platform offers additional advantages. Next generation sequencing approaches of the PDAC transcriptome have revealed prognostic and predictive subtypes that will most likely be of clinical relevance in the near future (\[[@R12]\], \[[@R13]\], \[[@R14]\], \[[@R15]\]). Most recently, Bailey et al. using NGS expression analysis defined 4 subtypes comprising: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics \[[@R14]\]. In the same way, miRNA clusters have been associated with chemosensitivity of PDAC stem cells \[[@R38]\]. It appears feasible that transcriptomic analysis of gene panels in EUS FNA may be used for molecular stratification of pancreatic tumors as the basis to personalize therapeutic decisions, e.g. in a neoadjuvant treatment situation.

mRNA/miRNA diagnostics is not suited for cyst fluid analysis of cystic tumors {#s3_2}
-----------------------------------------------------------------------------

Pancreatic cysts detected by imaging in asymptomatic patients may correspond to a variety of pathologies ranging from benign cysts (pseudocysts, serous cystic adenomas (SCA), true cysts) and premalignant or malignant cystic neoplasias (mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), solid pseudopapillary neoplasias (SPN), cystic pancreatic neuroendocrine neoplasias (cpNEN), serous cystadenocarcinomas). However, since up to 50-60% of the incidental pancreatic cysts detected by imaging show connections to pancreatic duct, they most likely represent IPMNs. One drawback of our study is that the complete set of data obtained from the combined mRNA/miRNA array did not allow to reliably identify cystic pancreatic neoplasias. Previous studies have reported that miRNA\'s, and in particular miR-21, miR155, miR-196a and miR-210, were able to differentiate malignant from non-malignant cystic lesion and in particular IPMNs (\[[@R22]\]; also see (\[[@R22]\] for an overview). Matthaei and coworkers \[[@R39]\] have used high-throughput miRNA analysis, followed by qRT-PCR in the same FFPE and pancreatic cyst fluid specimens, to develop a logistic regression model comprising 9 miRNAs, and correctly separated high risk from low risk pancreatic cysts with a sensitivity of 89% and a specificity of 100%. Wang et al. \[[@R40]\] used Next-Generation Sequencing (NGS) to study miRNA expression in a small number of EUS-FNAs from low-risk cysts (n = 6), high-risk cysts (n = 8), and PDACs (n = 3). Overall they found 13 up- and 2 downregulated miRNAs that, however, could not be all confirmed in validation experiments in the same and other studies (e.g.\[[@R22]\]). Frampton et al. in the most recently published trial reported that none of the miRNAs that were evaluated in EUS-FNA were able to separate benign non-mucinous (i.e. SCA and inflammatory/pseudocysts) from mucinous pancreatic cysts (i.e. MCN and IPMN) \[[@R22]\].

To summarize, our results and the results reported by other groups indicate that at present miRNA/mRNA diagnostics alone may be too variable to be reliably used in the clinical routine for the differentiation of pancreatic cysts. This may perhaps be resolved by introducing another genomic level in our multi-omic diagnostic platform. In a recent multi-center, retrospective study of 130 patients with resected pancreatic cystic neoplasms, cyst fluid was analyzed to identify mutations in genes known to be mutated in pancreatic cystic neoplasms (*BRAF*, *CDKN2A*, *CTNNB1*, *GNAS*, *KRAS*, *NRAS*, *PIK3CA*, *RNF43*, *SMAD4*, *TP53*, and *VHL*) \[[@R41]\]. With this combined analyses, the authors identified molecular markers and clinical features that classified cyst type with 90%-100% sensitivity and 92%-98% specificity. The molecular marker panel correctly identified 67 of the 74 patients who did not require surgery and thereby reduced the number of unnecessary operations by 91%.

It can thus be anticipated that a multi-omics diagnostic platforms as the one described here, combining mRNA, miRNA and mutational analyses with conventional diagnostic tests, such as cyst fluid CEA and cytology, will have the highest accuracy for the differentiation of the various types of benign and malignant pancreatic cysts.

Limitations and outlook {#s3_3}
-----------------------

Despite our promising results we recognize that our study has limitations. Our multi-omics platform comprises miRNAs from previously published studies selected for being specific for PDAC, and not for allowing to differentiate between other types of inflammatory, benign and malignant bilio-pancreatic masses. Our study is certainly underpowered concerning the various different types of bilio-pancreatic tumors, since these tumors are rare and FNA-material is difficult to obtain. This small sample size in some of the groups may have led to nonsignificant results due to a type II error. Furthermore, it may be argued that surgical FNAs may not be completely identical to the clinical situation, but we feel that this is a strength of our study, since histopathologically verified diagnoses for every single case are available as gold standard.

Our study provides evidence that a multi-omics platform assessing both, mRNA and miRNA biomarkers, is suitable for a molecular differentiation of suspect solid pancreatic masses. Further refinement of the selection of mRNA/miRNA markers will be done to allow the diagnosis of prognostic and predictive molecular PDAC subclasses such as those recently reported by Bailey and coworkers \[[@R14]\], that may have the potential to individualize the choice of neoadjuvant treatment. The limitations encountered in differentiating malignant and benign pancreatic cystic neoplasias was not completely unexpected based on the variable results reported by other groups. We are presently further developing the multiomics platform to allow additional mutational analyses of the genes that are known to differentiate pancreatic cystic neoplasias (\[[@R41]\], \[[@R42]\]) on the same platform in a single experimental step. We expect that this multi-omics platform will form an invaluable addition to the diagnostic workup of EUS-FNA biopsies of suspect solid and cystic pancreatic lesions.

MATERIALS AND METHODS {#s4}
=====================

Tissue and biopsy samples {#s4_1}
-------------------------

Since histological confirmation of diagnosis was an indispensable requirement for the validation of the performance of the diagnostic array, we focused on patients who received surgical resection of pancreaticobiliary masses for the purposes of this study. A total of 143 "surgical FNAB" (sFNAB) samples were performed from tumor masses immediately after resection using an 18G needle attached to a 20ml syringe, as previously described \[[@R11]\]. Biopsy material was expelled into 500 μl of RLT buffer (Qiagen) and the needle flushed again with the same volume of RLT buffer. Samples were stored at -80°C until processing. These sFNAB provided both accurate sampling of the tumor mass and subsequent histological evaluation of the very same tissue specimen.

Samples were provided by the surgery departments at the Ruprecht Karls University Heidelberg, Technical University Munich, and Philipps-University Marburg. Informed consent was obtained from all patients prior to using tissue or biopsy samples. The study was approved by the local ethics committees at the Universities of Marburg (Germany), Munich (Germany), and Heidelberg (Germany).

RNA isolation, mixed TaqMan arrays and qRT-PCR analyses {#s4_2}
-------------------------------------------------------

Total RNA was isolated using the mirVana PARIS Kit (Thermo Fisher Scientific). We have previously developed protocols for simultaneous reverse transcription and pre-amplification of mRNA and miRNA targets as well as simultaneous analysis of mRNA and miRNA targets on a single TaqMan Array microfluidic card \[[@R23]\]. In short, 4 μL of RNA (20-200 ng) were reverse transcribed by combining a custom MicroRNA RT Primer Mix and a gene-specific pooled mRNA preamp Primer Mix (Thermo Fisher Scientific) using the TaqMan® microRNA Reverse Transcription Kit (Thermo Fisher Scientific). 5 μL of the reverse transcription product were used for pre-amplification using a custom gene-specific preamp mRNA/miRNA Primer Mix (Thermo Fisher Scientific) and the TaqMan® PreAmp Master Mix (Thermo Fisher Scientific). For qRT-PCR, the pre-amplified product was mixed with "TaqMan® Universal PCR Master Mix, No AmpErase UNG" (Thermo Fisher Scientific) and the appropriate amount of H~2~O, and subsequently loaded into the ports of the TaqMan array cards (2 loading ports to cover the total of 96 reaction chambers). RealTime PCR was performed on a 7900HT Fast Real-Time PCR System (with TaqMan® Array Block) (Thermo Fisher Scientific), using universal cycling conditions (95°C/10 min, then \[95°C/15 sec, 60°C/60sec\] for 40 cycles).

Raw C~t~ values were normalized separately for mRNA and miRNA genes, respectively. To this end, C~t~ values of the reference genes (RPLP0, PPIA, RPL37A, RPL30, RPS17 for mRNA genes; RNU44 and RNU48 for miRNAs) were averaged and subtracted from the C~t~ values of the individual marker genes. The resulting ΔC~t~ values were then used for biomarker selection and sample classification.

Details of the array composition are provided in Table [1](#T1){ref-type="table"}; raw data can be accessed at <http://www.staff.unimarburg.de/~buchhol3/DiagArray/>

Biomarker selection {#s4_3}
-------------------

In our experiments, we applied a biomarker selection process as a preprocessing step to the multivariate training of the classification model. The biomarkers that were discarded by the selection process were considered neither for the training nor for the application of the classification model \[[@R43], [@R44]\].

For the standalone evaluation of miRNA-markers, we exhaustively screened through all 2^9^-1 = 511 marker combinations, which was not applicable for the higher dimensional profiles of combined mRNA and miRNA markers.

For the combined analysis, the mRNA and miRNA markers were ranked according to the modified version of Threshold Number of Misclassification (TNoM) score \[[@R46]\]. The markers that achieved the highest scores on the training data were passed to the classification model. We conducted experiments with top lists of 1 up to 88 markers.

The basic version of the TNoM score calculates the accuracy of an univariate single threshold classifier for each individual marker \[[@R45]\]. For our experiments, we utilized a slightly modified version of the TNoM, which also takes into account the class-wise number of samples (TNoM~cw~) \[[@R46]\]. The TNoM~cw~ score can be seen as the mean sensitivity and specificity of a single threshold classifier.

Classification model {#s4_4}
--------------------

We utilized a linear support vector machine (SVM) as multivariate classification model \[[@R47]\]. The decision boundary of a linear SVM can be seen as a linear hyperplane that separates feature space in two decision regions (e.g. PDAC/CP) (Figure [5iii](#F5){ref-type="fig"}). The SVM is designed as a large margin classifier, which maximizes the margin between the training samples and the decision boundary. The cost parameter of the SVM was fixed to a value of one. In our experiments, the input of the SVM is restricted to the biomarkers (mRNA/miRNA levels) selected by the biomarker selection process.

Validation strategy {#s4_5}
-------------------

All marker selection experiments are conducted as 10×10 cross-validation experiments \[[@R48]\]. The 10×10 cross-validation procedure splits the available set of samples into 10 subsets (folds) of approximately equal size (Figure [2](#F2){ref-type="fig"}). The folds are repetitively grouped into independent training and validation sets. Nine folds are used for marker selection and training a classification model. The remaining fold is used for the validation of the used classifier. The procedure is repeated for each individual fold. In order to reduce sampling effects, the cross-validation is calculated for ten permutations (runs) of the overall dataset leading to 10×10 individual training/ test splits. The mean accuracy, sensitivity and specificity are reported. All experiments have been conducted in the TunePareto framework \[[@R49]\].

Calculation of sensitivity, specificity and diagnostic accuracy {#s4_6}
---------------------------------------------------------------

Histopathological evaluation of tumor tissue was used as the gold standard for diagnosis. For each diagnostic class, sensitivity of the molecular diagnostic procedure was calculated by dividing the number of true positive (TP) calls by the sum of the numbers of true positive and false negative (FN) calls: $\frac{\text{TP}}{\left( {\text{TP } + \text{ FN}} \right)}$

Specificity was defined as the number of true negative (TN) calls divided by the sum of the numbers of true negative and false positive (FP) calls: $\frac{\text{TN}}{\left( {\text{TN } + \text{ FP}} \right)}$

Diagnostic accuracy was defined as the total number of samples correctly assigned to their respective classes divided by the number of all classification calls made in the analysis.
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